比索洛尔与米力农治疗慢性肺源性心脏病的对比观察  

Comparative study of bisoprolol and milrinone in treatment of chronic pulmonary heart disease

作　　者：陈小刚[1] 

机构地区：[1]江西省丰城矿务局总医院,江西宜春331141

出　　处：《中国当代医药》2014年第26期72-73,76,共3页China Modern Medicine

基　　金：江西省宜春市科技计划项目(宜科鉴字[2011]第32号)

摘　　要：目的比较比索洛尔与米力农治疗慢性肺源性心脏病的临床效果。方法选择于本院治疗的慢性肺源性心脏病患者120例,将其随机分为比索洛尔组(60例)和米力农组(60例),比索洛尔组采用比索洛尔治疗,米力农组采用米力农治疗,观察两组患者的治疗效果及治疗前后各项指标的变化。结果治疗后比索洛尔组患者的6 min步行距离、心率均大于米力农组,差异有统计学意义(P<0.05);比索洛尔组不良反应发生率低于米力农组,差异有统计学意义(P<0.05);米力农组患者的心功能、血气指标优于比索洛尔组,差异有统计学意义(P<0.05)。结论在慢性肺源性心脏病的治疗中,比索洛尔与米力农疗效均较好,但也均存在局限性,临床在选用时应根据患者的具体情况,选择合适的药物治疗。Objective To compare the clinical efficacy of bisoprolol and milrinone in the treatment of chronic pul-monary heart disease. Methods 120 cases of patients with chronic pulmonale heart disease were selected and randomly divided into bisoprolol group （60 cases） and milrinone group （60 cases）,bisoprolol was given to the bisoprolol group,the milrinone group were treated with milrinone.The curative effect of two groups,and changes of the indicators before and after treatment were compared. Results The aspect of 6 min walking distance and heart rate of bisoprolol group was better than that of milrinone group,the difference was significant （P〈0.05）;The incidence of adverse reactions in biso-prolol group was lower than that of milrinone group,the difference was significant （P〈0.05）;However,the cardiac func-tion,blood gas of milrinone group was better than that of bisoprolol group,the difference was significant （P〈0.05）. Con-clusion In the treatment of chronic pulmonary heart disease,the efficacy of bisoprolol and milrinone is good,but all have limitations,when chosing appropriate pharmacologic therapy,it should be according to the specific circumstances of pa-tients.

关 键 词：比索洛尔 米力农 慢性肺源性心脏病 

分 类 号：R541.5[医药卫生—心血管疾病]